Werner Gladdines (@gladdinesw) profile picture

Seasoned allround drug development professional with main interest in development of life changing therapies in rare neurological and oncology indications. c

Leiden, Nederland
Joined December 2009
Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)Photo by Werner Gladdines (@gladdinesw)
Werner Gladdines retweeted
๐Ÿงญ Board update at Immunic: Michael W. Bonney has been appointed new Chair of our Board of Directors. ๐Ÿง  With more than three decades of experience in the biopharmaceutical industry, including deep expertise in #MultipleSclerosis (#MS) and central nervous system (#CNS) markets, Mike brings valuable perspectives as we advance our clinical programs and prepare for upcoming milestones. His background spans senior leadership roles at Biogen, including for the launch and commercial success of MS drug Avonexยฎ, as well as CEO of Cubist Pharmaceuticals and roles of increasing responsibility at Zeneca Pharmaceuticals. His strong experience further strengthens our Board as we continue to advance our phase 3 #ENSURE trials in relapsing multiple sclerosis (#RMS) and plan to initiate a confirmatory phase 3 program in primary progressive multiple sclerosis (#PPMS). We also thank Simona Skerjanec for her dedicated leadership as Interim Chairperson and her continued role on our Board. ๐Ÿ™ Get all the details here: bit.ly/4uWM1wW $IMUX
1
4
6
309
Werner Gladdines retweeted
๐Ÿ“ข Patent Update ๐Ÿ›ก๏ธ The European Patent Office, @EPOorg, has granted a key European patent covering label-relevant dosing regimens for #Immunicโ€™s lead candidate, our #Nurr1 activator and #DHODH inhibitor, across all indications, including #MultipleSclerosis (#MS). ๐Ÿ‡ช๐Ÿ‡บ ๐Ÿ’Š The patent broadly protects #vidofludimus and its salt, solvate and free acid forms used according to the label-mandated dosing scheme. It is expected to provide protection in Europe into 2038 and may be eligible for a Supplementary Protection Certificate (SPC), potentially extending market exclusivity into 2043.๐Ÿง  ๐Ÿงฉ The #patent was previously granted by the U.S. Patent and Trademark Office, @uspto, in 2023 and supports Immunicโ€™s multi-layered #IntellectualProperty strategy for the drug with protection expected at least into 2041 in the United States and 2039 in Europe. ๐Ÿ‘‰ Learn more here: bit.ly/46Tyqg9 #DrugDevelopment $IMUX #IMU838
3
6
200
We are #hiring a working student in #communications! Are you creative, communicative, and ready to dive into the world of #biotech? Join our #PR and #IR team in Grรคfelfing, just outside of Munich! โœจ Curious about public and investor relations at #Immunic, learn more here: ๐Ÿ‘‰ imux.com/careers $IMUX #nowhiring #jobopportunity #applynow
3
3
338
๐Ÿ“ข #Immunic announces completion of enrollment for both phase 3 #ENSURE trials in relapsing #MultipleSclerosis (#RMS) and presents additional data underlining the positive outcome of the phase 2 CALLIPER trial in progressive mulitple sclerosis (PMS) โœจ ๐Ÿ“„ Get all the details here: bit.ly/4dOw840 #vidofludimus #IMU838 #neurology #neuroprotection #MS #PMS #MSResearch $IMUX
3
5
188
๐Ÿ“ข #๐—œ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐—ฐ ๐—”๐—ป๐—ป๐—ผ๐˜‚๐—ป๐—ฐ๐—ฒ๐˜€ ๐—ฃ๐—ฟ๐—ถ๐—ฐ๐—ถ๐—ป๐—ด ๐—ผ๐—ณ ๐—ข๐˜ƒ๐—ฒ๐—ฟ๐˜€๐˜‚๐—ฏ๐˜€๐—ฐ๐—ฟ๐—ถ๐—ฏ๐—ฒ๐—ฑ $๐Ÿฒ๐Ÿฑ ๐— ๐—ถ๐—น๐—น๐—ถ๐—ผ๐—ป ๐—จ๐—ป๐—ฑ๐—ฒ๐—ฟ๐˜„๐—ฟ๐—ถ๐˜๐˜๐—ฒ๐—ป ๐—ฃ๐˜‚๐—ฏ๐—น๐—ถ๐—ฐ #๐—ข๐—ณ๐—ณ๐—ฒ๐—ฟ๐—ถ๐—ป๐—ด ๐Ÿ’ฐ Today, we announced the pricing of an underwritten #PublicOffering, securing approx. $65 million in initial gross proceeds, with the potential to receive up to an aggregate of $130 million of additional gross proceeds if all tranches are exercised in full for cash. ๐Ÿ“ˆ The net proceeds will support the continued advancement of our clinical development pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, as well as general corporate purposes. ๐Ÿ”— Learn more here: bit.ly/3HtI2UU $IMUX #immunology #biotechnology
1
4
4
307
๐Ÿšจ #๐—œ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐—ฐ ๐—”๐—ป๐—ป๐—ผ๐˜‚๐—ป๐—ฐ๐—ฒ๐˜€ ๐—ฃ๐—ผ๐˜€๐—ถ๐˜๐—ถ๐˜ƒ๐—ฒ ๐—ฃ๐—ต๐—ฎ๐˜€๐—ฒ ๐Ÿฎ #๐—–๐—”๐—Ÿ๐—Ÿ๐—œ๐—ฃ๐—˜๐—ฅ ๐—ง๐—ฟ๐—ถ๐—ฎ๐—น ๐—ฅ๐—ฒ๐˜€๐˜‚๐—น๐˜๐˜€! ๐Ÿšจ Key highlights: ๐Ÿ”น 20% reduction in relative risk of 24-week confirmed disability worsening (24wCDW) events in overall #PMS study population compared to placebo ๐Ÿ”น 30% reduction in relative risk of 24wCDW events compared to placebo in high unmet need population of #PPMS ๐Ÿ”น Consistent reduction of disability worsening in subpopulations without inflammatory lesions at baseline ๐Ÿ”น 29% reduction in relative risk of 24wCDW events in patients without gadolinium-enhancing lesions at baseline compared to placebo ๐Ÿ”น 20% reduction in annualized rate of thalamic brain volume loss compared to placebo ๐Ÿ”น Confirmed favorable safety and tolerability profile observed in previous clinical trials; no new safety signals identified ๐Ÿ‘‰ Join our webcast today at 8am ET: bit.ly/4iDSTZs All details: โ–ถ๏ธ bit.ly/42XimHr #vidofludimus #IMU838 #MultipleSclerosis #MS #neurology $IMUX
2
4
1
9
2,456
๐Ÿง  How is #Immunic advancing potential new #MS treatment options? Our phase 3 #ENSURE trials can continue as planned, according to a recent positive interim analysis. Learn more details in @BioWorldโ€™s latest article: โžก๏ธ bit.ly/3NHoTid #MultipleScerlosis #PMS #RMS #Vidofludimus $IMUX #Immunic
4
2
242
๐Ÿ“ข$IMUX announced a ๐—ฝ๐—ผ๐˜€๐—ถ๐˜๐—ถ๐˜ƒ๐—ฒ outcome of the phase 3 #ENSURE interim analysis of #vidofludimus calcium in #RMS! An unblinded IDMC confirmed futility criteria were not met & recommended continuing the trial without changes. Learn more details here: โ–ถ bit.ly/4dUGzld or join #Immunic's webcast today 8am ET: โ–ถ bit.ly/48n36Gg #ClinicalTrials #IMU838 #MS #MultipleSclerosis #Neuroprotection #Nurr1 #DHODH
1
3
10
564
๐Ÿ™ As #ECTRIMS2024 comes to a close, the $IMUX team is grateful to everyone who made it so valuable! ๐Ÿค Thank you to all who stopped by to meet with us. Together, we are moving forward to find new treatments for progressive and relapsing #MultipleSclerosis. @ECTRIMS #MS #Immunic
3
1
7
452
I am honored and excited about my new role as Chief Development Officer at @ImmunicInc. The Nasdaq tower display is a proud moment, and I am grateful for the team's support and hard work that made this possible. A big thank you to @JessyBrett and the @Nasdaq team for the gesture
๐ŸŽ‰ Congratulations, once again, on your #promotion to Chief Development Officer, Werner! Your hard work and dedication have truly paid off. This display at the #Nasdaq tower is well-deserved. Here's to many more successes and milestones ahead! ๐Ÿ‘ $IMUX #Immunic @NasdaqExchange
1
3
141
๐ŸŽ‰ Congratulations, once again, on your #promotion to Chief Development Officer, Werner! Your hard work and dedication have truly paid off. This display at the #Nasdaq tower is well-deserved. Here's to many more successes and milestones ahead! ๐Ÿ‘ $IMUX #Immunic @NasdaqExchange
3
1
6
429
Werner Gladdines retweeted
Join us in welcoming @ImmunicInc to the Closing Bell. ๐Ÿ›Ž๏ธ $IMUX is developing a pipeline of next-generation selective oral therapies focused on offering patients with chronic inflammatory and autoimmune diseases new and clinically meaningful treatment options. #NasdaqListed
5
5
11
3,598
Thank you, @TheStevieAwards for rewarding us with 3 Gold & 1 Bronze Stevie Awards for our #MS R&D Webcast & website design. Now, we want to challenge our team even further & secure the prize for the most creative winning photo. Please like, retweet & support! #StevieWinner2023
3
4
189
Today, 9:30am-4:00pm CT, at @DDWMeeting, Dr. Franziska Buriรกnek, Senior Medical Director at $IMUX, presents an e-poster, entiteled: "First-in-Human Trial of #IMU856, an Orally Available Regulator Of Barrier Function For The Treatment Of #CeliacDisease". #DDW #DDW2023 #Immunic
3
7
274
โ€ผ๏ธNEWSโ€ผ๏ธ During @DDWMeeting, today, we present clinical and preclinical data of #IMU856, including its #ModeOfAction as a potent small molecule modulator of #SIRT6. Learn more: https://teapawt.net/t.co/4mDUIzGk5e #DigestiveDiseaseWeek #DDW #DDW2023 #Immunic $IMUX
1
3
6
279
โ–ถ๏ธMay 3-4: Meet $IMUX's VP, Clinical Development Operations, Werner Gladdines at the "Outsourcing in Clinical Trials (OCT) Europe". Let's learn about #FutureTrends and get the latest knowledge about disruptors in the #ClinicalTrials space. @Arena_Pharma #OCTEurope2023
4
5
301
Exciting times at Immunic. The clinical development operations group is further expanding its capabilities with 2 new exciting roles in the area of clinical compliance and vendor management. These roles have direct impact on the future of our three oral sโ€ฆlnkd.in/ewFU48FZ
26
Today is #WorldIBDDay2022! $IMUX is developing a potential therapy to alleviate the suffering of people with #UlcerativeColitis. #VidofludimusCalcium is in a phase 2 clinical trial in moderate-to-severe #UC, for which top-line data is expected in June. #IBDhasNoAge #GameOverIBD
3
3
$IMUX to participate in upcoming conferences: https://teapawt.net/t.co/Ee1RuzVvfP @BRileyFinancial Neuro & Ophthalmology Conference (Apr 27-28); @ArenaIntOCT Outsourcing in Clinical Trials Europe (May 4-5); @BioCentury #BioEquity Europe (May 16-18; 23-24); @DDWMeeting #DDW2022 (May 21-24)
2
5